5 analysts have shared their evaluations of Eton Pharmaceuticals (NASDAQ:ETON) during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Eton Pharmaceuticals, revealing an average target of $24.4, a high estimate of $33.00, and a low estimate of $17.00. Marking an increase of 22.0%, the current average surpasses the previous average price target of $20.00.

Deciphering Analyst Ratings: An In-Depth Analysis

An in-depth analysis of recent analyst actions unveils how financial experts perceive Eton Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into Eton Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Eton Pharmaceuticals analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Eton Pharmaceuticals

Key Indicators: Eton Pharmaceuticals's Financial Health

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Eton Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 46.9%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Eton Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 6.07%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Eton Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 4.26%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Eton Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 1.85%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: With a below-average debt-to-equity ratio of 0.27, Eton Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst Ratings: What Are They?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.